What I am working with: retatrutide · eight weeks · 4 °C.
I keep seeing this stated as a fact with no explanation attached, and unexplained facts make me suspicious.
My background is quantitative but not chemical, so I can follow an equation more easily than a hand-wave.
Why does this happen, and what would falsify the usual explanation?
On the detail: start by separating chemical degradation from physical degradation, because they fail differently and they are detected differently. Chemical degradation changes the molecule and shows up as new peaks on a chromatogram. Physical degradation aggregates the molecule and often shows up as nothing at all on reverse-phase HPLC, because the aggregate never makes it onto the column.
On re-freezing something that thawed in transit: if it arrived as a lyophilised solid that warmed but never got wet, re-freezing costs you nothing except the thermal cycle. If it arrived as a solution that thawed, re-freezing adds a second transition and therefore a second dose of ice-front shear. The asymmetry is worth internalising.
| State | Condition | Usable window | Basis |
|---|---|---|---|
| Lyophilised solid | −20 °C, sealed, dry | 24–36 months | Supplier guidance |
| Lyophilised solid | 2–8 °C, sealed | 12–24 months | Supplier guidance |
| Lyophilised solid | 25 °C, sealed | 4–8 weeks | Extrapolated (Arrhenius) |
| Lyophilised solid | 40 °C, sealed | 1–2 weeks | Extrapolated |
| Solution, preserved | 2–8 °C | 28 days | USP microbiological convention |
| Solution, preserved | 25 °C | 3–7 days | Extrapolated |
| Solution, unpreserved | 2–8 °C | 24 hours | USP microbiological convention |
Windows for the solid state are chemical; windows for solution are microbiological and usually shorter than the chemical limit.
Put another way, light matters for specific residues rather than in general. Tryptophan and to a lesser extent tyrosine and methionine are photo-labile; a sequence without them is largely indifferent to ambient light over the timescales in question. Amber glass is cheap insurance rather than a requirement.
The licensed semaglutide and tirzepatide presentations carry in-use periods of several weeks at room temperature in their labelling, which is the closest thing to real stability data in this space — and it applies to a buffered, surfactant-containing, preservative-containing formulation, not to a reconstituted research vial.
One qualification: none of this addresses sterility. A vial can be chemically pristine and microbiologically compromised, and a chromatogram will not tell you which.
The single highest-value change most people can make is buying a cheap logging thermometer, because it converts an assumption about their storage into a record.
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse resultsMechanically, the honest answer is that published stability data for these specific molecules in a research-grade presentation essentially does not exist, so what you get is extrapolation from the licensed formulations and from general peptide chemistry. That extrapolation is reasonable. It is still extrapolation.
Freeze-concentration is the mechanism people miss. As ice forms, everything that is not water is excluded into a shrinking unfrozen fraction, so the local concentration of peptide, buffer salts and preservative rises sharply. If the buffer components crystallise at different rates, local pH can shift by more than a unit. That is why a phosphate-buffered solution can behave badly on freezing while an unbuffered one is fine.
In practice, practical thermal arithmetic for a shipment: a single 250 g phase-change pack in a thin-walled polystyrene box holds sub-ten-degrees for roughly 24 to 48 hours in a 25 °C ambient, and considerably less at 35 °C. Any lane taking eight to fourteen days is therefore not temperature-controlled for most of its duration regardless of what was in the box, which is the argument for shipping the material lyophilised.
The Arrhenius relationship underpinning accelerated stability testing is the basis of ICH Q1A, which is why accelerated studies at 40 °C and 75 per cent relative humidity are used to predict shelf life at 25 °C. The same relationship lets you reason about a warm transit lane, with the same caveats about extrapolation.
Worth stating: research-use-only material has no stability programme behind it at all, so any beyond-use date you apply is your own construct.
The practical rule is that time and temperature multiply, so shorten whichever one you control.
edited 30 Mar 2025 by Dr_Ilse_Vandenberg — updated for the 2026 guidance change
On the detail: the lyophilised solid is far more robust than anything anyone says about it, and the solution is far less robust. Most of the confusion in this area comes from advice about one being applied to the other.
The 28-day figure for a reconstituted preserved vial is microbiological, not chemical. Chemically, a well-behaved peptide at 5 mg/mL at 4 °C will typically lose well under a per cent of content per month. The reason to respect the date is bioburden, and bioburden is a function of how many times you have opened it, not of the calendar.
The underlying point is that aggregation is the failure mode that reverse-phase HPLC is worst at detecting, because a large soluble aggregate may not elute at all and an insoluble one is filtered out during sample preparation. If your purity result comes back normal but the vial looks hazy, believe the vial. Size-exclusion chromatography is the method that sees this.
General guidance on lyophilised peptide storage from the major synthesis houses converges on minus twenty degrees for long-term storage of solids and refrigerated storage for solutions in use, with the explicit note that repeated freeze-thaw of solutions should be avoided. It is consistent advice precisely because it follows from the chemistry rather than from a study.
The limitation is that you cannot detect slow aggregation by eye until it is well advanced, so a clear vial is weak evidence of an intact one.
Minimise transitions rather than minimising temperature. One freeze and one thaw is fine; five is a different question.
The underlying point is that degradation is not one process, and which one dominates depends on the condition you are asking about. In solution at refrigerated temperature the rate-limiting pathway is usually deamidation and hydrolysis; at room temperature aggregation overtakes them; frozen, the damage happens during the transitions rather than during the hold.
For the solid state, residual moisture is the dominant variable. A cake at two per cent water is considerably more stable than the same cake at six per cent, because water is both a reactant in hydrolysis and a plasticiser that lowers the glass transition temperature. This is why a desiccant in the outer packaging is not theatre, and why opening a cold vial in a humid room is a genuine error — you condense water onto the cake.
Where community-submitted samples with known thermal excursions have been tested at Janoshik or Medutest, the recurring finding is that lyophilised material tolerates warm transit far better than intuition suggests, while reconstituted material shipped warm does not. The asymmetry is consistent enough to plan around.
I would be careful about generalising across sequences. Stability is sequence-specific, and a rule derived from semaglutide will not transfer cleanly to a tri-agonist with different residues in different local environments.
Store solid, store cold, store dry, and reconstitute what you will use rather than what fits in the vial.
On the detail: freeze-thaw damage happens at the moving ice front, not at the storage temperature. Once the sample is frozen solid and cold, very little is happening. The damage is done during freezing and thawing, which is why the number of cycles matters and the duration of the hold mostly does not.
Adsorption to the container is a real loss at low concentration. For a peptide at 0.1 mg/mL in an untreated glass vial, single-digit percentage losses to the wall are plausible; at 5 mg/mL it is negligible. This is one of several reasons not to reconstitute to a very dilute working solution and store it.
Deamidation kinetics for asparagine in peptides are well characterised and strongly sequence-dependent: the residue following the asparagine dominates the rate, with glycine and serine at the n+1 position accelerating it by an order of magnitude relative to bulkier residues. That is why two peptides in the same buffer at the same temperature can have quite different shelf lives.
The caveat is that "within specification" and "unchanged" are different claims. A vial can lose a few per cent of content and still be usable for its purpose while no longer matching its certificate.
If the material arrived warm and it was lyophilised, test it and proceed on the result. If it arrived warm and it was in solution, the result is more likely to be interesting than reassuring.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.